NCOR2
NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Prostate cancer and 5 more.
Overview
Transcriptional corepressor that mediates the transcriptional repression activity of some nuclear receptors by promoting chromatin condensation, thus preventing access of the basal transcription. Acts by recruiting chromatin modifiers, such as histone deacetylases HDAC1, HDAC2 and HDAC3. Required to activate the histone deacetylase activity of HDAC3.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.90, animal model 0.54, genetic association 0.16, somatic mutation 0.91). IntOGen calls it a driver in 10 cohorts (3 activating, 6 loss-of-function), covering Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, High-Grade Glioma, NOS, Leiomyosarcoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Prostate cancer and 5 more.
- 1 · What it is
NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Prostate cancer and 5 more.
- 2 · What goes wrong in cancer
Transcriptional corepressor that mediates the transcriptional repression activity of some nuclear receptors by promoting chromatin condensation, thus preventing access of the basal transcription.
- 3 · How drugs use it
No product in this corpus aims at NCOR2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7673 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y618 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000196498 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: colorectal cancer 0.58, prostate cancer 0.52, melanoma 0.53, skin cancer 0.55, breast cancer 0.56, lung cancer 0.53 (GraphQL API, CC0)); IntOGen NCOR2 (driver in 10 cohorts (Act 3, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional corepressor that mediates the transcriptional repression activity of some nuclear receptors by promoting chromatin condensation, thus preventing access of the basal transcription. Acts by recruiting chromatin modifiers, such as histone deacetylases HDAC1, HDAC2 and HDAC3. Required to activate the histone deacetylase activity of HDAC3. Involved in the regulation BCL6-dependent of the germinal centre (GC) reactions, mainly through the control of the GC B-cells proliferation and survival. Recruited by ZBTB7A to the androgen response elements/ARE on target genes, negatively regulates androgen receptor signalling and androgen-induced cell proliferation. Isoform 1 and isoform 4 have different affinities for different nuclear receptors. Location: Nucleus (UniProt). Locus 12q24.31 (HGNC).
- Colorectal cancer: Open Targets association 0.58 with colorectal cancer (MONDO_0005575); IntOGen driver in 2 cohorts (COADREAD)
- Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)
- Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)
- Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Sarcomas: IntOGen driver in 1 cohort (LMS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 6 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: High-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"NCOR2" OR ABSTRACT:"NCOR2" OR TITLE:"nuclear receptor corepressor 2" OR ABSTRACT:"nuclear receptor corepressor 2" OR TITLE:"Nuclear receptor corepressor 2" OR ABSTRACT:"Nuclear receptor corepressor 2" OR TITLE:"SMRTE" OR ABSTRACT:"SMRTE" OR TITLE:"TRAC-1" OR ABSTRACT:"TRAC-1" OR TITLE:"CTG26" OR ABSTRACT:"CTG26") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NCOR2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFAT4
Shares Mesothelioma, Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetNCOR1
Shares Mesothelioma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetLATS2
Shares Mesothelioma, Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetPTPRB
Shares Mesothelioma, Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetBAP1
Shares Mesothelioma, Oesophageal cancer, Hepatocellular carcinoma, Breast cancer (all types).
- TargetPBRM1
Shares Mesothelioma, Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetNFKB2
Shares Mesothelioma, Skin cancer (all types), IntOGen, Open Targets Platform.
- TargetSETDB1
Shares Mesothelioma, Hepatocellular carcinoma, Breast cancer (all types), IntOGen.